Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Rituximab Antibody ELISA Kit

Human, Mouse and Rat ELISA Kit Colorimetric assay for quantification of Human, Mouse and Rat .
Catalog No. ABIN4886399

Quick Overview for Rituximab Antibody ELISA Kit (ABIN4886399)

Target

Rituximab Antibody

Reactivity

Human, Mouse, Rat

Detection Method

Colorimetric

Method Type

Bridging ELISA

Detection Range

7.8-62.5 ng/mL

Application

ELISA

Sample Type

Plasma, Serum
  • Minimum Detection Limit

    7.8 ng/mL

    Purpose

    Quantification of antibodies to Rituximab

    Analytical Method

    Quantitative

    Specificity

    Anti-Rituximab antibodies

    Characteristics

    This immunogenicity assay employs the bridging ELISA technique.

    Components

    Coated microtiter plate, 96 wells
    QC samples - 4x50ul
    10X wash buffer - 25ml
    Assay buffer - 50ml
    1000X secondary antibody - 17ul
    1000X detection reagent - 17ul
    TMB - 12ml
    TMB stop solution - 12ml
    Plate sealers - 3

    Material not included

    Precision pipettes calibrated to deliver 5-1000μL
    Multi-channel pipette calibrated to deliver 50-200μL
    Plate shaker
    Disposable tips
    Vortex-Mixer
    Distilled or de-ionized water
    Microplate reader capable of reading 450nm with background subtrac
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Sample Volume

    15 μL

    Assay Time

    3.5 h

    Plate

    Pre-coated

    Protocol

    The Rituximab immunogenicity assay employs the bridging ELISA technique. A precoated 96 well capture antibody plate is provided. Quality control and test samples are pipetted into the appropriate wells. Anti-Rituximab present in biological matrices binds the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of anti-Rituximab present in test samples. Four levels of QC samples give a qualitative reference signal which can be used to determine the level (High, Medium, Low, Negative) of anti-Rituximab antibody in the unknown samples.

    Reagent Preparation

    Prepare only the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 2 mL concentrate to 18 mL ultra-pure water). Mix well. 2. Secondary antibody (1X) Preparation: Dilute secondary antibody with assay buffer 1/1000 before use (for examples add 12 μL concentrate to 12 mL of assay buffer). Mix well. 3. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 12 μL concentrate to 12 mL of assay buffer). Mix well.

    Sample Collection

    This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20 °C for up to 1 year.

    Sample Preparation

    Dilute QC samples and test samples 1/10 with assay buffer (for example add 30μL of prepared calibrator or sample to 270μL of assay buffer). Mix well. Do not store diluted samples. If test samples are out of range, then they may be further diluted.

    Assay Procedure

    This immunogenicity assay employs the bridging ELISA technique. Capture antibody is precoated onto a 96 well microplate. Quality control and test samples are pipetted into the appropriate wells. Anti-Rituximab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, secondary antibody is added to the wells and after a final wash a detection reagent is added. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of anti-Rituximab present in test samples. Four levels of QC samples give a qualitative reference signal which can be used to determine the level of antiRituximab antibody in the unknown samples. The color development is stopped and the intensity of the color is measured.

    Calculation of Results

    1. Because anti-drug antibodies will vary in terms of affinity and concentration, this assay provides a qualitative readout. As such the user should use the comparable positive controls when comparing interassay results. The provided controls are tested for comparability between lots and can be traced. 2. The anti-drug antibody titers in the test samples will fall in the range of high, medium, low or negative. We recommend each lab develop their own statistical cutpoint using methodologies as described by G. Shankar, et al. (2008). (Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharmaceutical and Biomedical Analysis 48:1267-1281). 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with assay buffer and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.

    Assay Precision

    Intra-assay precision: < 10%
    Inter-assay precision: < 10%

    Restrictions

    For Research Use only
  • Preservative

    Without preservative

    Precaution of Use

    Read manual completely before beginning

    Storage

    -20 °C

    Storage Comment

    Store kit components at -20°C unless specified otherwise. DO NOT USE past kit expiration date. Some vials contain a small amount of reagents. Spin tubes on pulse setting prior to opening.

    Expiry Date

    12 months
  • Target

    Rituximab Antibody

    Target Type

    Antibody

    Background

    Rituximab (Rituxan® ) is a chimeric mouse/human monoclonal antibody used for treating B cell malignancy, autoimmune conditions, and graft rejection by depleting B cells from the body.

    Gene ID

    931
You are here:
Chat with us!